How do you treat metastatic urothelial carcinoma after progression on immune checkpoint inhibitor?
No actionable mutation on NGS testing. What approved therapy do you prefer? Are there specific investigational agents currently in clinical trials that you find promising?
Do you think differently about someone who progresses on switch maintenance avelumab vs 1L (platinum ineligible) or salvage pembrolizumab?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · VCU Massey Comprehensive Cancer Center
Answered on
Agree with @Dr. First Last. Enfortumab Vedotin is the current standard after checkpoint inhibitors and platinum-based chemotherapy, with no targetable mutation. The response rates for subsequent chemotherapy in the platinum-refractory setting are generally poor. I used Ramicurimab-Docetaxel (Petryla...
Join for free or sign in to see the full answer